Clinical Trials Logo

Hyperparathyroidism, Primary clinical trials

View clinical trials related to Hyperparathyroidism, Primary.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04013100 Terminated - Clinical trials for Primary Hyperparathyroidism

Cohort Trial on Perioperative Localization Techniques of Parathyroid Adenomas

ParaCatI
Start date: January 1, 2014
Phase:
Study type: Observational [Patient Registry]

A prospective database of consecutive patients with hyperparathyroidism subject to surgery is created. Preoperative workup and operative findings are recorded in this registry to allow comprehensive analysis.

NCT ID: NCT01558115 Terminated - Clinical trials for Primary Hyperparathyroidism

Denosumab in Primary Hyperparathyroidism

Start date: January 2012
Phase: Phase 4
Study type: Interventional

Primary hyperparathyroidism (PHPT), a disease characterized by excess parathyroid hormone (PTH) and high blood calcium, is one of the most common endocrine disorders. PHPT is seen most often in postmenopausal women. Many patients with PHPT have low bone mineral density (BMD) when bone mass is measured by dual energy x-ray absorptiometry (DXA), primarily at the forearm. There is currently no effective medical therapy which increases bone density at the forearm in patients with PHPT. PTH both builds and breaks down bone, and the pathways by which PTH mediates these actions are beginning to be identified. Prior research suggests that RANKL, a molecule important in bone metabolism, responds to PTH, and that if the RANKL is inactivated, PTH is shifted towards building bone. The investigators will study the effect of Denosumab, a therapeutic agent that binds to and inactivates RANKL, in 28 postmenopausal women with PHPT. Our hypothesis is that Denosumab will increase bone mineral density in primary hyperparathyroidism. The study will last two years, and subjects will be randomly assigned to receive either placebo or Denosumab for the first year of the study. In the second year, all subjects will receive Denosumab. Denosumab (60 mg) or placebo will be given every 6 months by an injection just under the skin. Study procedures performed will include bone mineral density tests by DXA, high-resolution peripheral quantitative computed tomography (HR-pQCT) scans, and assessments of biochemical markers of calcium metabolism and bone turnover using both blood and urine samples of subjects with PHPT.

NCT ID: NCT00961701 Terminated - Clinical trials for Primary Hyperparathyroidism

Lipids Profile in Primary Hyperparathyroidism

LPHP
Start date: October 2009
Phase: N/A
Study type: Observational

Severe Primary hyperparathyroidism (PHP) has been associated with increased cardiovascular morbidity and mortality. Hypertension, dyslipidemia and impaired glucose tolerance were demonstrated in severe PHP, with improvement after surgery in these variables. Recent evidence suggests that the 'quality' rather than only the 'quantity' of low-density lipoprotein (LDL)-cholesterol exerts a direct influence on the cardiovascular risk. Thus, the proposed study protocol is intended to evaluate lipoprotein phenotype and LDL size and subclasses in patients with primary hyperparathyroidism.